{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:52:17Z","timestamp":1773391937763,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Evidence for the first-line treatment of venous thromboembolism (VTE) by use of direct oral anticoagulants (DOACs) is based on stratification by body-mass index (BMI) and total body weight, but does not consider body composition \u2013 defined as the distribution of fat mass (FM) and fat-free mass (FFM). Variability in body composition exists among patients with normal BMI, but is anticipated to be markedly greater in the context of overweight and obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The BIARIVA prospective, single-center, cross-sectional study was conducted to assess whether body composition affects blood coagulation monitoring parameters in patients on therapeutic-dose anticoagulant treatment for VTE with oral factor (F.) Xa inhibitors rivaroxaban or edoxaban. Patients were qualified for inclusion into the study if they were categorized into one of the specified BMI categories; 18\u201325, 30\u201335, or\u2009&amp;gt;\u200935\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Body composition was determined by two bioelectrical impedance analysis (BIA) methods. The primary endpoint was the association between body composition parameters and coagulation measurements in patients treated with rivaroxaban or edoxaban, assessed by correlation analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-six patients on rivaroxaban and 35 patients on edoxaban were finally analyzed. The main finding in this study was a significant negative correlation observed in the edoxaban group for the absolute FFM with anti-F.Xa and plasma concentration peak levels (BIA method 1: r\n                      <jats:sub>s<\/jats:sub>\n                      \u2009=\u2009\u22120.439,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008; BIA method 2: r\n                      <jats:sub>s<\/jats:sub>\n                      \u2009=\u2009\u22120.431,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010) and with the absolute increase from trough to peak in plasma concentration levels (BIA method 1 and 2: r\n                      <jats:sub>s<\/jats:sub>\n                      \u2009=\u2009\u22120.446,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) and in anti-F.Xa levels (BIA method 1: r\n                      <jats:sub>s<\/jats:sub>\n                      \u2009=\u2009\u22120.445,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007; BIA method 2: r\n                      <jats:sub>s<\/jats:sub>\n                      \u2009=\u2009\u22120.444,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). No significant correlations of body composition measures with coagulation parameters were found in the rivaroxaban group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that body composition might influence specific coagulation measurements in patients treated with edoxaban, but further research is required to finally determine the role of body composition in this context and to evaluate clinical implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1773664","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:46:28Z","timestamp":1773384388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism"],"prefix":"10.3389","volume":"13","author":[{"given":"Katharina","family":"Kurzmann-Guetl","sequence":"first","affiliation":[{"name":"Division of Angiology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah R.","family":"Leitner","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gary","sequence":"additional","affiliation":[{"name":"Division of Angiology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Avian","sequence":"additional","affiliation":[{"name":"Medical Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Beck","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Rabensteiner","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Prueller","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard B.","family":"Raggam","sequence":"additional","affiliation":[{"name":"Division of Angiology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[{"name":"Division of Angiology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Toplak","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Di Nisio","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST. Guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.3390\/jcm13133784","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in obese patients (BMI >\/= 30\u2005kg\/m(2)) with atrial fibrillation or venous thromboembolism: an updated systematic review and meta-analysis","volume":"13","author":"Karakasis","year":"2024","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/0115701611330090250130075810","article-title":"Comparative efficacy and safety of direct oral anticoagulants and warfarin in morbidly obese patients (BMI \\>40\u2005kg\/m2): a systematic review and meta-analysis","volume":"23","author":"Sagris","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.amjmed.2023.01.010","article-title":"Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel","volume":"136","author":"Rosovsky","year":"2023","journal-title":"Am J Med"},{"key":"B13","article-title":"Obesity and Overweight","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/nutrit\/nuw019","article-title":"Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications","volume":"74","author":"Franco","year":"2016","journal-title":"Nutr Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/oby.2011.36","article-title":"Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI","volume":"19","author":"Gomez-Ambrosi","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","article-title":"Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity","volume":"36","author":"Gomez-Ambrosi","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1182\/blood.2019003528","article-title":"How I treat obese patients with oral anticoagulants","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B21","article-title":"European Medicines Agency (EMA): Xarelto Euopean Public Assessment Report","year":""},{"key":"B22","article-title":"U.S. Food & Drug Administration (FDA): Rivaroxaban (Xarelto) Medication Guide","year":""},{"key":"B23","article-title":"European Medicines Agency (EMA): Lixiana Euopean Public Assessment Report","year":""},{"key":"B24","article-title":"U.S. Food & Drug Administration (FDA): Savaysa (Edoxaban) Medication Guide","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/1060028015578451","article-title":"Heparin-Calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?","volume":"49","author":"Gosselin","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ijlh.13692","article-title":"Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban","volume":"44","author":"von Horn","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"B32","article-title":"seca mBCA 515 manufacturer\u2019s manual","year":""},{"key":"B33","article-title":"MEDI CAL HealthCare GmbH. BIACORPUS RX 4000 manufacturer\u2019s manual","year":""},{"key":"B34","first-page":"614","article-title":"Biostatistics 104: correlational analysis","volume":"44","author":"Chan","year":"2003","journal-title":"Singapore Med J"},{"key":"B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0035-1550193","article-title":"Vergleich zweier BIA Ger\u00e4te zur Ermittlung der K\u00f6rperzusammensetzung","volume":"40","author":"Sekli","year":"2015","journal-title":"Aktuelle Ern\u00e4hrungsmedizin"},{"key":"B36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MCO.0b013e32830b5f23","article-title":"Assessment methods in human body composition","volume":"11","author":"Lee","year":"2008","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0200465","DOI":"10.1371\/journal.pone.0200465","article-title":"Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures","volume":"13","author":"Achamrah","year":"2018","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1517\/13543784.17.6.925","article-title":"Rivaroxaban, an oral direct factor Xa inhibitor","volume":"17","author":"Piccini","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/bjh.17009","article-title":"Body weight is negatively associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users","volume":"191","author":"Borst","year":"2020","journal-title":"Br J Haematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1055\/s-0040-1715834","article-title":"Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study","volume":"121","author":"Martin","year":"2021","journal-title":"Thromb Haemost"},{"key":"B42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/rth2.12146","article-title":"Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/bcp.12727","article-title":"Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and\/or pulmonary embolism\u2013the hokusai-VTE phase 3 study","volume":"80","author":"Niebecker","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1055\/s-0040-1716540","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial","volume":"121","author":"Boriani","year":"2021","journal-title":"Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11239-020-02199-0","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data","volume":"51","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/1060028019886092","article-title":"Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight","volume":"54","author":"Perales","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.thromres.2019.08.021","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs","volume":"182","author":"Spyropoulos","year":"2019","journal-title":"Thromb Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11239-022-02661-1","article-title":"Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States","volume":"54","author":"Berger","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/10600280221089008","article-title":"Management of venous thromboembolism in morbid obesity with rivaroxaban or warfarin","volume":"56","author":"Weaver","year":"2022","journal-title":"Ann Pharmacother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.thromres.2016.09.010","article-title":"Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience","volume":"147","author":"Arachchillage","year":"2016","journal-title":"Thromb Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1773664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:46:29Z","timestamp":1773384389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1773664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":53,"alternative-id":["10.3389\/fcvm.2026.1773664"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1773664","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1773664"}}